thrombin receptor peptide sfllrnp has been researched along with bradykinin (1-5) in 1 studies
| Studies (thrombin receptor peptide sfllrnp) | Trials (thrombin receptor peptide sfllrnp) | Recent Studies (post-2010) (thrombin receptor peptide sfllrnp) | Studies (bradykinin (1-5)) | Trials (bradykinin (1-5)) | Recent Studies (post-2010) (bradykinin (1-5)) |
|---|---|---|---|---|---|
| 92 | 10 | 29 | 32 | 4 | 6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biaggioni, I; Brown, NJ; Byrne, DW; Luther, JM; Malave, HA; Murphey, LJ; Petro, J; Pretorius, M; Vaughan, DE | 1 |
1 other study(ies) available for thrombin receptor peptide sfllrnp and bradykinin (1-5)
| Article | Year |
|---|---|
Bradykinin and its metabolite bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans.
Topics: Adult; Bradykinin; Dose-Response Relationship, Drug; Female; Fetus; Fibrinolysis; Humans; Male; Peptide Fragments; Plasminogen Activator Inhibitor 1; Platelet Aggregation; Platelet Aggregation Inhibitors; Thrombin | 2006 |